Pretreatment ¹⁸F-FDG Uptake Heterogeneity Predicts Treatment Outcome of First-Line Chemotherapy in Patients with Metastatic Triple-Negative Breast Cancer.

ABSTRACT:

Background

Intratumoral heterogeneity of ¹⁸F-fluorodeoxyglucose (¹⁸F-FDG) uptake in primary tumor has proven to be a surrogate marker for predicting treatment outcome in various tumors. However, the value of intraindividual heterogeneity in metastatic diseases remains unknown. The aim of this study was to evaluate pretreatment positron emission tomography/computed tomography (PET/CT) ¹⁸F-FDG-based heterogeneity for the prediction of first-line treatment outcome in metastatic triple-negative breast cancer (mTNBC).

Materials and methods

mTNBC patients from three clinical trials (NCT00601159, NCT01287624, and NCT02341911) with whole-body ¹⁸F-FDG PET/CT scan before first-line gemcitabine/platinum were included. Heterogeneity index (HI)

SUBMITTER: Gong C 

PROVIDER: S-EPMC6263118 | biostudies-literature | 2018 Oct

REPOSITORIES: biostudies-literature